Artivion initiates enrollment in persevere clinical trial

Study designed to evaluate the safety and efficacy of the amds hybrid prosthesis to treat acute debakey type i aortic dissections & support u.s. fda pma submission atlanta , july 27, 2022 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has initiated enrollment in the persevere clinical trial to determine if patients with an acute debakey type i aortic dissection can be treated safely and effectively using the amds hybrid prosthesis. the trial is designed to support the company's forthcoming application to the u.s. food and drug administration (fda) for premarket approval of the amds.
AORT Ratings Summary
AORT Quant Ranking